Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2018
Price : $35 *
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Otitis media; Pneumococcal infections
- Focus Therapeutic Use
- Acronyms Nunavik2
- 16 Jul 2018 Results assessing prevalence of middle ear abnormalities published in the Vaccine.
- 01 Mar 2017 Planned End Date changed from 1 Sep 2016 to 31 Dec 2017.
- 01 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 31 Dec 2017.